Navigation Links
International molecular screening program for metastatic breast cancer AURORA at IMPAKT

While research has made great strides in recent decades to improve and significantly extend the lives of patients with early breast cancer, the needs of patients with advanced or metastatic disease have largely been ignored. Moreover, despite the fact that the overall breast cancer death rate has dropped steadily over the last decade and significant improvements in survival have been made, metastatic breast cancer represents the leading cause of death among patients with the disease.

In this context the Breast International Group (BIG) recently launched AURORA, which will use molecular screening to improve our understanding of metastatic breast cancer and its response or lack of response to available drug therapies. In total 1300 women and men from about 60 hospitals in 15 European countries are expected to take part in the programme. Over time, BIG hopes to expand the programme well beyond Europe to involve several 1000 more patients.

Dr Martine Piccart-Gebhart, Chair of BIG and Director of the Medicine Department of the Institut Jules Bordet, strongly believes in this research programme and says: "It is almost unethical that we continue to treat women with metastatic breast cancer when we have so little knowledge of their disease. We now have powerful technologies for investigating the molecular landscape of tumours, and we have an obligation to women to establish AURORA as a large translational research effort that can hopefully lead to more effective treatments in the future".

Within AURORA, metastatic and primary breast cancer tissue specimens will be collected and screened with a panel of more than 400 cancer-related genes for the first time on a large scale. Plasma and blood samples will also be collected, and any samples not analysed immediately will be stored in an independent bio-repository to enable future research. An innovative bioinformatics platform has been developed to support the collection of AURORA data. These data are being collected in a way that will allow sharing and collaborating in the context of other initiatives started by researchers in North America.

AURORA will enable scientists to understand both why breast cancer metastasises and why some patients respond poorly to standard treatment, while others respond very well. Whenever possible, patients participating in AURORA will be offered to participate in a clinical trial testing new and promising drugs that target the specific genetic characteristics of their tumours. The ultimate hope is that AURORA will benefit patients by leading us to both better treatments and to finding cures for the women and men affected by this disease.


Contact: Cecilia Waldvogel
Breast International Group (BIG)-aisbl

Related medicine news :

1. CMNH celebrates International Day of the Midwife with new £9.3m program in Kenya
2. Researchers at LSTM part of the international team to sequence the tsetse genome
3. International Communication Association to hold Annual Conference in Seattle, Washington
4. Proteomics International biomarker study closer to a CDx test for diabetic kidney disease
5. Immunotherapy innovator wins 2014 Canada Gairdner International Award
6. Ottawa researcher receives international award for obesity research
7. Menopause International re-launching as Post Reproductive Health
8. International study shows majority of children unaware of cigarette warning labels
9. International Journal of Surgery affiliated with New York Surgical Society
10. Beaumont holds first international congress on underactive bladder
11. UTA professors new book explores international response time to foreign conflicts
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important to take certain medications ... from Austin, Texas, has identified a solution. , She developed a prototype for MOTION ... As such, it eliminates the need to turn on a light when taking medication ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical ... the primary prevention of cardiovascular diseases during the 15th Annual Women’s Health ...
(Date:10/13/2017)... N.J. (PRWEB) , ... October 13, 2017 , ... The ... Holly Day Market. Featuring a collection of specialty vendors and unique items from across ... personalized and quality-focused health and wellness services offered by the VNA. The boutique ...
(Date:10/13/2017)... ... 13, 2017 , ... Talented host, actor Rob Lowe, is ... a new episode of "Success Files," which is an award-winning educational program broadcasted ... each subject in-depth with passion and integrity. , Sciatica occurs when the sciatic ...
(Date:10/12/2017)... ... October 12, 2017 , ... First ... compliance program management, will showcase a range of technology and learning solutions at ... (NCAL) Convention and Expo to be held October 14–18, 2017 at the Mandalay ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
(Date:9/19/2017)... medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound energy ... ... Jim Bertolina, PhD ... Tom Tefft ... executive Josh Stopek , PhD, who has led R&D and business development teams at ...
Breaking Medicine Technology: